Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 1;72(3):355-361.
doi: 10.1093/gerona/glw220.

Clinical Trials Targeting Aging and Age-Related Multimorbidity

Mark A Espeland  1 , Eileen M Crimmins  2 , Brandon R Grossardt  3 , Jill P Crandall  4 , Jonathan A L Gelfond  5 , Tamara B Harris  6 , Stephen B Kritchevsky  7 , JoAnn E Manson  8 , Jennifer G Robinson  9 , Walter A Rocca  10   11 , Marinella Temprosa  12 , Fridtjof Thomas  13 , Robert Wallace  9 , Nir Barzilai  14 ; Multimorbidity Clinical Trials Consortium
Affiliations

Clinical Trials Targeting Aging and Age-Related Multimorbidity

Mark A Espeland et al. J Gerontol A Biol Sci Med Sci. .

Abstract

Background: There is growing interest in identifying interventions that may increase health span by targeting biological processes underlying aging. The design of efficient and rigorous clinical trials to assess these interventions requires careful consideration of eligibility criteria, outcomes, sample size, and monitoring plans.

Methods: Experienced geriatrics researchers and clinical trialists collaborated to provide advice on clinical trial design.

Results: Outcomes based on the accumulation and incidence of age-related chronic diseases are attractive for clinical trials targeting aging. Accumulation and incidence rates of multimorbidity outcomes were developed by selecting at-risk subsets of individuals from three large cohort studies of older individuals. These provide representative benchmark data for decisions on eligibility, duration, and assessment protocols. Monitoring rules should be sensitive to targeting aging-related, rather than disease-specific, outcomes.

Conclusions: Clinical trials targeting aging are feasible, but require careful design consideration and monitoring rules.

Keywords: Chronic diseases; Clinical trial design; Geroscience.

PubMed Disclaimer

References

    1. St Sauver JL, Boyd CM, Grossardt BR, et al. Risk of developing multimorbidity across all ages in an historical cohort study: differences by sex and ethnicity. BMJ Open. 2015;5:e006413. doi:10.1136/bmjopen-2014-006413 - PMC - PubMed
    1. Kochanek KD, Murphy SL, Xu JQ, Tejada-Vera B. Deaths: final data for 2014 National Vital Statistics Reports. Vol 65, No 4 Hyattsville, MD: National Center for Health Statistics; 2016.
    1. Miller RA. Extending life: scientific prospects and political obstacles. Milbank Q. 2002;80:155–174. - PMC - PubMed
    1. Goldman DP, Cutler D, Rowe JW, et al. Substantial health and economic returns from delayed aging may warrant a new focus for medical research. Health Affairs. 2013;32:1698–1705. - PMC - PubMed
    1. Fabbri E, Zoli M, Gonzalez-Freire M, Salive M, Studenski SA, Ferrucci L. Aging and multimorbidity: new tasks, priorities, and frontiers for integrated gerontological and clinical research. JAMDA. 2015;16:640–647. - PMC - PubMed

Publication types